PMID- 10593867
OWN - NLM
STAT- MEDLINE
DCOM- 20000106
LR  - 20190516
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 13
IP  - 15
DP  - 1999 Dec
TI  - Interleukin-18 acts as an angiogenesis and tumor suppressor.
PG  - 2195-202
AB  - Interleukin-18 (IL-18), also called interferon-gamma (IFN-gamma)-inducing factor, 
      has recently been characterized as a potent IFN-gamma-inducing cytokine. We now 
      report that IL-18 is a novel antiangiogenic and antitumor cytokine. In vitro, 
      IL-18 specifically inhibits fibroblast growth factor-2-stimulated proliferation 
      of capillary endothelial cells. In vivo, IL-18 is sufficiently potent to suppress 
      the fibroblast growth factor-induced corneal neovascularization by systemic 
      administration in mice. This cytokine also inhibits embryonic angiogenesis in the 
      chick chorioallantoic membrane assay. Systemic and intralesional administrations 
      of IL-18 produce a significant suppression of the growth of murine T241 
      fibrosarcoma in syngeneic C57Bl6/J and immunodeficient SCID mice. The antitumor 
      effect appears to be potent because an average of >75% inhibition of primary 
      tumor growth was observed at a dose of 50 microg/kg/day. In cell culture, murine 
      T241 fibrosarcoma cells are insensitive to recombinant IL-18 at concentrations 
      that significantly inhibit endothelial cell proliferation. Immunohistochemical 
      studies of tumor tissues reveal hypovascularization of the IL-18-treated tumors. 
      These results suggest that IL-18 may participate in the regulation of a switch of 
      tumor angiogenesis.-Cao, R., Farnebo, J., Kurimoto, M., Cao, Y. Interleukin-18 
      acts as an angiogenesis and tumor suppressor.
FAU - Cao, R
AU  - Cao R
AD  - Laboratory of Angiogenesis Research, Microbiology and Tumor Biology Center, 
      Karolinska Institute, S-171 77 Stockholm, Sweden.
FAU - Farnebo, J
AU  - Farnebo J
FAU - Kurimoto, M
AU  - Kurimoto M
FAU - Cao, Y
AU  - Cao Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-18)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Division/drug effects
MH  - Chick Embryo
MH  - Disease Models, Animal
MH  - Endothelium, Vascular/cytology/drug effects
MH  - Injections, Subcutaneous
MH  - Interleukin-18/pharmacology/*physiology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Neovascularization, Physiologic/physiology
MH  - Recombinant Proteins/metabolism
EDAT- 1999/12/14 00:00
MHDA- 1999/12/14 00:01
CRDT- 1999/12/14 00:00
PHST- 1999/12/14 00:00 [pubmed]
PHST- 1999/12/14 00:01 [medline]
PHST- 1999/12/14 00:00 [entrez]
AID - 10.1096/fasebj.13.15.2195 [doi]
PST - ppublish
SO  - FASEB J. 1999 Dec;13(15):2195-202. doi: 10.1096/fasebj.13.15.2195.